OneCell Diagnostics bags $16M to help limit cancer recurrence using AI

Quick Summary:

The startup combines the circulating tumor cell DNA with its RNA and cell surface protein testing.

A phlebotomist visits the patient’s home to collect the blood drawn in two tubes: one for detecting circulating tumor DNA (ctDNA) and the other for detecting circulating tumor cells.

OneCell has secured an IP to capture and isolate the circulating tumor cell from a 10 ml blood draw.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Jagmeet Singh

Category: StartupsBusiness

Markets: United StatesGeorgiaIndia

Topics: OneCell Diagnostics Exclusive Celesta Capital Startups

Source Website Secure: Yes (HTTPS)

News Sentiment: Positive

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-11-21 @ 04:00:00 (1 days ago)

News Timezone: GMT -5:00

News Source URL: techcrunch.com

Language: English

Article Length: 883 words

Reading Time: 5 minutes read

Sentences: 40 lines

Sentence Length: 23 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © TechCrunch

News ID: 23742676

View Article Analysis

About TechCrunch

Main Topics: StartupsBusiness

Official Website: techcrunch.com

Year Established: 2005

Headquarters: United States

News Last Updated: 1 days ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT -5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #1

Publisher Details

Frequently Asked Questions